Stem Cell Therapy at Stem Cell Institute on PBS-TV Dallas-Fort Worth this Sunday! PBS KERA TV-13

Brenda Watson Show. KERA
PBS TV (KERA 13) in Dallas-Fort Worth – Go inside our clinic and lab in Panama, and watch interviews with 3 patients. The other episode follows a knee patient through the treatment process at Dr. RIordan’s orthopedic stem cell clinic in Southlake, Texas. Sunday, January 29th from 12pm – 1pm.

Stem Cells I

Riordan-McKenna Institute – Stem Cell Therapy for Orthopedics

Take a journey with marathon runner and knee patient Jim Morella as he undergoes a stem cell augmented arthroscopic knee procedure. Peer inside the operating room as Dr. McKenna harvests stem cells from Jim’s bone marrow, prepares them, and injects them into his knee. Tag along with Brenda as she interviews Jim at home following his recovery.

Dr. McKenna discusses Jim’s case with Brenda and explains why stem cell injections alone are not necessarily the best solution to knee problems, including Jim’s. He also touches upon the FDA’s current role regarding regulations.

Dr. Riordan talks about how the proprietary amniotic membrane tissue product used by RMI can enhance bone marrow stem cell therapy and the safety aspects of such treatments.

Dr. McKenna Stem Cell Augmented Surgery 3

Stem Cells II

Stem Cell Institute in Panama: Spinal Cord Injury, Multiple Sclerosis (MS), Rheumatoid Arthritis (RA) and More…

Brenda Watson takes you inside the Stem Cell Institute and Medistem Labs in Panama. If you have ever wondered what stem cell therapy is like in Panama, this show is for you.

See inside the laboratory and clinic as Brenda follows three patients through the treatment and recovery process: Sam Harrell (MS), Juan Jose Ballareno (Spinal Cord Injury) and Todd Rinehart (RA).

Meet the team as she interviews key players:

Neil Riordan, PhD, Founder and Chief Scientist of Medistem Labs, explains how the Panamanian government regulates stem cells in Panama. He discusses how HUCT-MSCs work on RA before delving into the subject of clinical trials in Panama and the USA.

Medical director, Jorge Paz Rodriquez, MD discusses how HUCT-MSCs work and why they can be transplanted without immune system rejection.

Rodolfo Fernandez, Medistem Panama Laboratory Director talks about tissue selection and processing.

Stem Cell Therapy for Knee Pain and Injuries – Teresa Hamrick’s Story

Registered Nurse and Stem Cell Recipient, Teresa Hamrick tells her uplifting story about how bone marrow stem cell therapy augmented with AlphaGEMS amniotic tissue product got her out of a wheelchair. Teresa received her treatments at the Riordan-McKenna Institute (RMI) in Southlake, Texas. RMI is Dr. Riordan’s new orthopedic stem cell clinic. For more information, please visit: www.rmiclinic.com

PRESS RELEASE – Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound

Dallas-Fort Worth (PRWEB) August 28, 2015 – Riordan-McKenna Institute founders, stem cell expert Neil Riordan, PhD and orthopedic surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by Amniotic Therapies in Dallas, Texas, resulted in complete healing of an otherwise non-healing surgical knee wound.

Before-After.262x175The case involved a 78-year-old male, who presented with a non-healing surgical wound following a right total knee replacement performed six weeks prior. The patient had not responded after 6 weeks of conservative wound care and the wound showed no signs of healing.

Dr. McKenna irrigated the wound in the operating room under pulse lavage and then placed two AlphaPATCH dry amniotic membranes (4 cm x 4 cm) over the wound before dressing it.

At the two-week follow-up visit, a central scab had formed. At four-weeks, the wound had completely scabbed over. At eight-weeks the scab had just fallen off and the wound was healing well with immature skin representing the size of a penny. At the ten-week follow-up visit, the wound was completely healed.

The case report, entitled “Case Report Of Non-Healing Surgical Wound Treated With Dehydrated Amniotic Membrane” is published in the July issue of the Journal of Translational Medicine. Authors include Dr. Riordan, Dr. McKenna, Troy Chandler, PA-C, and Ben George, PA-C. This milestone in Dr. Riordan and Dr. McKenna’s ongoing study of biologic wound healing using amniotic tissue products and stem cells is the third peer reviewed journal article on regenerative medicine published by the Riordan McKenna Institute.

A common misconception is that dehydrated amniotic membrane products like AlphaPATCH contain live stem cells. Although dehydrated amniotic membrane does not contain any stem cells, it does contain a number of growth factors that promote healing and stimulate the body’s own stem cells to become activated and likely behave more similar to stem cells in a younger person.

“It’s gratifying to have this new tool in my toolbox. I treated conservatively and was getting nowhere. Even in a patient with a significant smoking history and decreased blood flow to his legs, we were able to achieve this result. Chronic wounds can be very frustrating for both the patient and the caregiver,” remarked Troy Chandler, PA-C, who participated in the patient’s treatment.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.

BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

www.rmiclinic.com

801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

About Amniotic Therapies

Based in Dallas, Texas, Amniotic Therapies specializes in the processing and distribution of human amniotic tissue products for the biologic and regenerative medicine segments of the healthcare market. Amniotic Therapies’ mission is to provide superior human amniotic tissue products that naturally enhance the body’s healing ability, providing patients with improved healing.

Amniotic Therapies is registered with the U.S. Food and Drug Administration (FDA) and is in the process of receiving accreditation from the American Association of Tissue Banks.

www.amniotictherapies.com

11496 Luna Rd. Suite 800
Dallas, Texas
75235

Tel: (972) 465-0496

Stem cell treatment in Panama shows signs of hope for local Belle Fourche boy

By Karla J. Flack, Black Hills Pioneer

James Habeck and his mother Melissa

James Habeck and his mother Melissa

BELLE FOURCHE — Three-year old James Habeck and his family have returned from a medical trip to Panama. His mother Melissa Habeck said they are noticing signs of improvement as a result of the stem cell treatment James received at the Stem Cell Institute in Panama City, Panama.

Treatment is hoped to provide James with relief from some of the complications caused by his cerebral palsy and allow him to do things a toddler would normally be able to do such as talk, sit-up, walk, turn himself over in bed at night so he would have fewer sleeping issues, and use his hands and feet. Some with James’ condition have tight muscles, but James’ muscles are just limp.

Medical professionals told Melissa that the new stem cells would live actively in James for six months. During those six months of cell life, whatever James learns and the strength he gains should remain.

The Habecks returned to Belle Fourche June 7 and shortly thereafter James’ extensive line-up of therapy treatments began. He is on a fast track of learning and is currently undergoing speech, occupational, and physical therapies in both Rapid City and Belle Fourche.

This week he was fitted for a wheelchair and evaluated to see if an augmented and alternative communication device could help him communicate. If he can train his eyes to look at a particular item on the device his family will know what he is trying to communicate to them.

“They feel like he is stuck in his body, and that it is possible; he understands 75 percent of what I say to him,” Melissa said.
The Hebeck’s trip began May 31 and entailed an hour flight to Denver and six hours from Denver to Panama. James had never flown but he did well with the flights.

Melissa asked doctors why hospitals in the U.S. don’t offer the treatment James needs. The answer was FDA (Food and Drug Administration) regulations.

A Southlake, Texas, center recently opened. The extent of services offered is not being released at this time. [Note: This statement is not accurate. The Riordan-McKenna Institute in Southlake, Texas treats orthopedic conditions such as knee injuries and arthritis and rotator cuff injuries with a combination of bone marrow aspirate concentrate and AlphaGEMS amniotic membrane product. More information can be found at www.rmiclinic.com]

The Habecks met an athletic coach who was receiving stem cell treatment in Panama for multiple sclerosis. He said he was walking with a walker prior to his treatments. A filming crew was with him documenting his progress as he no longer has to use a walker after undergoing multiple stem cell treatments.

Melissa said staff at the Stem Cell Institute said a number of autistic patients come there for treatment. Heart failure, osteoarthritis, rheumatoid arthritis, spinal cord injury, and autoimmune diseases are also treated at the institute.
James had stem cells that were extracted from donated umbilical cords injected intravenously into his arms. The injections went fine some days but other days were problematic because his veins would rupture and the medical team would have to find a new vein. Melissa said by the end of the week both her and James were crying, but the staff was excellent in dealing with it.

“They were using a butterfly needle to access the veins but collapsing veins were still an issue and James was getting tired of getting poked with needles,” she said.

Melissa said she has been in contact with individuals who tried stem cell treatments that were not successful. She said people who had their own cells taken and then transferred back into their bodies told her their treatments were unsuccessful. She also said some who had gone to other countries and did the spinal stem cell procedures said those results weren’t positive. Melissa said she feels very positive about James’ treatment.

He has a special walker that he can use if someone pushes it for him.

“He took off by himself in his walker after treatment,” Melissa said.

He has also started trying to use his arms and legs to stabilize himself. He has more neck control and is trying to use his neck to raise his head. He has also shown improvement in efforts to gain eye contact with those who are talking to him. He has to fight for control as his eyes both stray separate ways.

Melissa said that when James was younger he tried to walk but then stopped trying; then he tried to sit. She was told that often times people with cerebral palsy have to abandon one thing to learn something else. Treatment will hopefully allow for a number of items to be learned and motor skills to be tackled simultaneously.

“He cried when they took the iPad from his sight on the plane and when the augmented and alternative communication device was taken from him,” Melissa said. This type of expression in connection with wanting something has not been something he was able to do in the past. She was happy he cried to have it back.

The Belle Fourche community rallied around the Habecks with a fundraiser March 22 wherein $20,000 was raised for James to have the stem cell treatment. Belle Fourche Police Chief Scott Jones and Belle Fourche Fire Chief Kip Marshall were taped to a building while raising funds and businesses donated door prizes. The Naja Shriners clowns helped raise funds Danielle Butler, James’ caregiver, organized the fundraiser. Many people joined together to help James. Melissa said she couldn’t believe it when it became possible for them to go for treatment.

Stem Cells Used to Successfully Treat Chronic Achilles Tendon Injury

Ocala, FL, October 06, 2014 –(PR.com)-Biologic Therapies, Inc. (BTI), a company that specializes in the design and development of medical devices and procedures for the regenerative medicine market, announced today that its products have been used to successfully treat a chronically injured Achilles tendon with stem cell therapy.

A case report, titled ‘Minimally Invasive Autologous Bone Marrow Concentrate Stem Cells in the Treatment of the Chronically Injured Achilles Tendon: A Case Report’, was authored by Biologic Therapies’ Chief Medical Director, Dr. R. Wade McKenna, and Chief Scientific Officer, Dr. Neil H. Riordan, founders of the Riordan-McKenna Institute in Southlake, Texas, USA (www.rmiclinic.com).

The case involved a 56-year-old female patient complaining of a painful “knot” in her left Achilles tendon. The pain limited her ability to perform daily activities such as shopping or being up on her feet for longer than 30 minutes. She had been an active tennis player and recreational athlete, but had not been able to play tennis or jog for ten years. She reported significant pain when relaxing and great pain when walking. The patient had been to multiple physicians and had followed ten years of standard treatment with stretches and anti-inflammatories. She refused multiple offers of invasive surgery that could not promise a return to tennis.

On physical examination by Dr. R. Wade McKenna, the patient had a large, palpable knot in the Achilles tendon, very noticeable and acutely tender. An MRI scan showed severe hypertrophic changes with marked tendinopathy.

The patient received a point-of-care stem cell therapy treatment in Dr. McKenna’s office as an outpatient procedure using Biologic Therapies products. The physician drew bone marrow from her tibia (shin) bone, processed the marrow in a centrifuge to concentrate the stem cells and growth factors, then injected the stem cells and growth factors into and around her injured Achilles tendon. Prior to the injection of the concentrated stem cells and growth factors, an injection of local anesthesia was given to prevent pain. The patient reported little to no pain during or after the procedure.

After six weeks the patient reported no pain at rest and minimal pain while walking. After eight weeks, there was even less pain while walking. The knot was less than 50% of the pre-treatment size and was relatively non-tender to touch. She was back to playing tennis without significant pain or difficulty. After ten weeks the patient was doing much better. An MRI scan showed even more reduction in the size of the knot, and pain was reduced even further. After 32 weeks an MRI scan showed near complete healing of the treated Achilles tendon.

The case report has been published by the scientific journal, CELLR4, the Official Journal of The Cure Alliance. The report can be seen on the CELLR4 website at http://www.cellr4.org/article/1100.

According to Luke Whalen, Biologic Therapies’ CEO, “This is an extremely important development for Biologic Therapies. The case report shows that stem cell therapy is an effective treatment for chronic Achilles tendon injury, which has not been documented before. The report also shows that stem cell therapy for this type of injury can be administered in a physician’s office as a point-of-care outpatient procedure using Biologic Therapies products. There is no need for hospitalization and surgery as would have been the case previously.

“Another important aspect of the publication of this case report is that the scientific journal it was published by is one of the most prestigious publications in the regenerative medicine industry. The members of the CELLR4 Journal Editorial Board that reviewed and approved the report are literally the ‘who’s who’ of regenerative medicine professionals from around the world. We are honored that they chose to publish the report. This helps to reinforce Biologic Therapies’ position as a global leader in regenerative medicine,” said Whalen.

The CELLR4 Editorial Board is led by Editor in Chief, Camillo Ricordi
from the Cell Transplant Center and Diabetes Research Institute at the University of Miami, Miami, Florida, USA. Other editorial staff of note include the Associate Editor for Asia, Jianming Tan
of Fuzhou General Hospital, Xiamen University, China; Assistant Editor, Antonello Pileggi of the Cell Transplant Center and Diabetes Research Institute at the University of Miami, Miami, Florida, USA; and Assistant Board member Arnold I. Caplan
from Case Western Reserve University, Cleveland, Ohio, USA.

In the late 1980’s, Dr. Arnold Caplan and colleagues developed and patented the technology to isolate adult human mesenchymal stem cells (MSCs) from bone marrow and to preserve their multi-potency (Caplan et al., 2001; Koc et al., 1999; Lennon et al., 2006). Adult human MSCs are capable of differentiating into a number of tissue types including bone, cartilage, muscle, marrow, tendon, ligament, adipocytes, and connective tissue.

Over 100 scientists, physicians, researchers and educators from around the world make up the CELLR4 Editorial Board. A complete listing of the Board members can be found at http://www.cellr4.org/editorial-board

About CELLR4
CELLR4 (http://www.cellr4.org) is a scientific journal with particular focus on cellular repair, replacement, regeneration, reprogramming and differentiation. Its scope ranges from fundamental new discoveries in basic science to translational, clinical trials and delivery of novel therapeutic options. As the official journal of the international non-profit organization The Cure Alliance, CELLR4 serves as a platform for discussion of challenges and opportunities on the path to the development of new treatments, independently from the disease target. CELLR4 publishes commentaries and opinion papers on regulatory, legal, and ethical issues, as well as information on global collaborative platforms and funding opportunities of interest to the field.

CELLR4 also serves as the official journal of the Fondazione Cure Alliance Onlus, another non-profit international organization that include physicians, scientists, patients, patient advocates, business and philanthropy leaders, with the mission to promote collaborative efforts worldwide, while addressing and working to resolve impediments and challenges on the path to develop cures for diseases now afflicting humankind. In this direction, the publication serves as a shared communication platform to discuss challenges and opportunities on the path to develop new treatments.

About Biologic Therapies
Based in Ocala, Florida, Biologic Therapies, Inc. (www.biologictherapies.com), is a company with a principal strategy of seeking out and developing innovative, proprietary and patented technologies to meet the needs of the rapidly emerging science of regenerative medicine, including stem cell therapy. Biologic Therapies provides groundbreaking medical technologies that significantly enhance the body’s natural healing ability, thereby providing patients with improved outcomes and quicker restoration of function. The Company’s products provide access to the biologics / regenerative medicine sector of the healthcare market.